ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2020; 10(10): 96-105


Genistein enhances cytotoxic and antimigratory activities of doxorubicin on 4T1 breast cancer cells through cell cycle arrest and ROS generation

Muthi Ikawati, Riris Istighfari Jenie, Rohmad Yudi Utomo, Nur Dina Amalina, Gagas Pradani Nur Ilmawati, Masashi Kawaichi, Edy Meiyanto.



Abstract
Download PDF Cited by 28 ArticlesPost

Genistein (Gen) demonstrates growth induction and inhibition on several cancer cells depending on the dose. By using triple-negative breast cancer metastatic cells, 4T1, this study aimed to evaluate the cytotoxic and anti-metastatic effects of Gen in combination with doxorubicin (Dox). Gen exhibited cytotoxic effects in dose- and time-dependent manners with an IC50 value of 50 μM. Interestingly, Gen in combination with Dox enhanced the growth inhibitory effect in 48 hours and caused increases in the G2/M phase arrest, as well as apoptosis. Gen alone increased cyclin B expression that may prevent the cells to enter anaphase. Moreover, the single treatment of Gen inhibited cell migration up to 45% in 24 hours. Under gelatin zymography and immunoblotting experiments, a combination of Gen and Dox subsided the activities of matrix metalloproteinase-9 and the expression level of Rac1, thereby showing the potency of Gen as an antimigratory agent. In accordance with the growth inhibitory effect, Gen also considerably stimulated the cellular reactive oxygen species production and autophagy activity. In conclusion, Gen increased the cytotoxic activity of Dox in 4T1 cells and inhibited cell migration.

Key words: genistein, doxorubicin; cytotoxic, antimigration, 4T1 breast cancer cell







Bibliomed Article Statistics

20
19
29
19
32
42
27
23
23
27
20
9
R
E
A
D
S

7

17

20

8

15

25

10

10

12

10

13

3
D
O
W
N
L
O
A
D
S
010203040506070809101112
2025

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.